Beta-microseminoprotein immunoreactivity as a new prognostic indicator of prostatic carcinoma.

Abstract

Human beta-microseminoprotein (beta-MSP), isolated from seminal plasma, is one of the proteins secreted by the prostate gland. To determine whether the beta-MSP immunoreactivity can be a prognostic indicator of prostatic carcinoma, the beta-MSP immunohistochemical distribution has been examined in needle biopsy specimens taken from 96 patients with prostatic carcinoma. Although no significant correlation was found between the beta-MSP immunoreactivity and the histological grade (Gleason score), patients with a positive beta-MSP expression had a significantly better prognosis than those with a negative beta-MSP expression (P = 0.01). Further, a multivariate analysis of six possible parameters (age, clinical stage, histological grade, serum prostatic acid phosphatase, beta-MSP immunoreactivity, and the type of initial treatment) has shown the difference in the beta-MSP immunoreactivity to be a significant, independent, prognostic indicator of prostatic carcinoma (P = 0.04).

• Authors: H Hyakutake, H Sakai, Y Yogi, R Tsuda, Y Minami, Y Yushita, H Kanetake, I Nakazono, Y Saito
• Journal: The Prostate (Prostate) Vol. 22 Issue 4 Pg. 347-55 ( 1993) ISSN: 0270-4137 [Print] United States
• PMID: 8497429 (Publication Type: Journal Article)

Chemical References

• Antigens, Neoplasm
• Prostatic Secretory Proteins
• Proteins
• Seminal Plasma Proteins
• beta-microseminoprotein

Topics

• Aged
• Aged, 80 and over
• Antigens, Neoplasm (analysis)
• Biopsy, Needle
• Humans
• Immunohistochemistry
• Male
• Middle Aged
• Multivariate Analysis
• Prognosis
• Proportional Hazards Models
• Prostatic Neoplasms (chemistry, diagnosis)
• Prostatic Secretory Proteins
• Proteins (analysis)
• Seminal Plasma Proteins
• Survival Analysis